<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67204">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02230956</url>
  </required_header>
  <id_info>
    <org_study_id>191622-145</org_study_id>
    <secondary_id>2014-001076-58</secondary_id>
    <nct_id>NCT02230956</nct_id>
  </id_info>
  <brief_title>BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of a single intra-articular injection of 2
      doses of BOTOX® (onabotulinumtoxinA) compared with placebo as treatment for knee
      osteoarthritis symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the 7-Day Average Daily Pain Score Using an 11-Point Scale</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC™) Pain Score Using an 11-Point Scale</measure>
    <time_frame>Baseline, Weeks 1, 4, 8, 12, 16, 20 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the WOMAC™ Physical Function Score Using an 11-Point Scale</measure>
    <time_frame>Baseline, Weeks 1, 4, 8, 12, 16, 20 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (GIC) Using a 7-Point Scale</measure>
    <time_frame>Weeks 1, 4, 8, 12, 16, 20 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the 7-Day Average Daily Worst Pain Score Using an 11-Point Scale</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA Dose 1 injection into the intra-articular space of the study knee on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA Dose 2 injection into the intra-articular space of the study knee on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Normal Saline) injection into the intra-articular space of the study knee on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>onabotulinumtoxinA</intervention_name>
    <description>onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.</description>
    <arm_group_label>OnabotulinumtoxinA Dose 1</arm_group_label>
    <arm_group_label>OnabotulinumtoxinA Dose 2</arm_group_label>
    <other_name>botulinum toxin Type A</other_name>
    <other_name>BOTOX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal Saline (placebo) injection into the intra-articular space of the study knee.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Painful osteoarthritis

          -  Able to discontinue anti-inflammatory drugs and analgesics

          -  Must be ambulatory without assistive walking devices

        Exclusion Criteria:

          -  Chronic pain conditions other than knee osteoarthritis

          -  Treatment with corticosteroids in the study knee within 12 weeks

          -  Treatment with hyaluronic acid in the study knee within 24 weeks

          -  Previous treatment with any botulinum toxin for any reason

          -  Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral
             sclerosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 11, 2016</lastchanged_date>
  <firstreceived_date>August 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
